Skip to main content


  • Poster presentation
  • Open Access
  • Efficacy of antidepressants in juvenile depression: meta-analysis

    • 1, 2, 3,
    • 3, 4,
    • 3, 5 and
    • 3
    Annals of General Psychiatry20087 (Suppl 1) :S350

    • Published:


    • Public Health
    • Placebo
    • Systematic Review
    • Randomise Control Trial
    • Fluoxetine


    Safety of antidepressants in children and adolescents is being questioned and their efficacy in juvenile depression remains uncertain. Our aim was to assess antidepressant efficacy in juvenile depression.

    Materials and methods

    Systematic review and meta-analysis of randomised controlled trials (RCTs) comparing responses to antidepressants, overall and by type, vs. placebo in depressed juveniles.


    Thirty drug-placebo contrasts in RCTs lasting 8 weeks (median), involved 2979 subjects (456 person-years) of average age 13.5 years. Meta-analysis yielded a modest pooled drug/placebo response rate ratio (RR=1.22, 95%CI: 1.15-1.31), with little separation among antidepressant-types. Findings were similar for rate differences (RD) and Corresponding number-needed-to-treat (overall NNT: 10; TCAs [13] > SRIs [9] > Others [8]). NNTs decreased with increasing age: children (22) > mixed-ages (11) > adolescents (8).


    Antidepressants of all types showed limited efficacy in juvenile depression, but fluoxetine might be more effective, especially in adolescents. Studies in children, severely depressed, hospitalised or suicidal juveniles are needed, and effective, safe, and readily accessible treatments for juvenile depression are urgently required.



    The authors thank the Royal College of Psychiatrists of England for awarding an Eli Lilly Travelling Fellowship to EMT, the Ph.D. program in Psychiatry of the University of Pisa, the Harvard School of Public Health doctoral program in Epidemiology, and the IDEA Foundation, Milan for supporting FS, and the Bruce J. Anderson Foundation and the McLean Private Donors Psychopharmacology Research Fund for research grants to RJB.

    Authors’ Affiliations

    MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK
    “Aghios Charalambos” Mental Health Unit, Heraklion, Crete, Greece
    Department of Psychiatry, Harvard Medical School and Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Massachusetts, USA
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Lucio Bini Mood Disorder Centre and Department of Psychology, University of Cagliari, Sardinia, Italy


    © Tsapakis et al.; licensee BioMed Central Ltd. 2008

    This article is published under license to BioMed Central Ltd.